bioAffinity Technologies, Inc. is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories at the University of Texas San Antonio (UTSA). The Company’s platform technology is being developed to diagnose, monitor and treat many cancers.
| Company: | bioAffinity Technologies, Inc. | |
| Headquarters Address: | 22211 W I-10, Suite 1206 | |
| San Antonio, TX 78257 | ||
| Main Telephone: | 5054009747 | |
| Website: | ||
| Type of Organization: | Private | |
| Industry: | Biotechnology | |
| Key Executives: | CEO: Maria Zannes | |
| Public Relations | ||
| Contact: | Julie Anne Overton | |
| Phone: | 5055770918 | |
| Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005775/en/
Source: bioAffinity Technologies, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20200610005775/en
